share_log

Roth Capital Initiates Coverage On BioRestorative Therapies With Buy Rating, Announces Price Target of $15

Roth Capital Initiates Coverage On BioRestorative Therapies With Buy Rating, Announces Price Target of $15

Roth Capital以买入评级启动对生物修复疗法的报道,宣布目标股价为15美元
Benzinga Real-time News ·  2022/12/07 08:14

Roth Capital analyst Jonathan Aschoff initiates coverage on BioRestorative Therapies (NASDAQ:BRTX) with a Buy rating and announces Price Target of $15.

Roth Capital分析师Jonathan Aschoff以买入评级启动对生物修复疗法(纳斯达克:BRTX)的报道,并宣布目标价为15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发